A Phase 1/2 interventional study of Mirdametinib 2mg and BGB-3245 5mg in Advanced Solid Tumor, sponsored by SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany. Terminated at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany (part of Merck KGaA, Darmstadt, Germany) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A Phase 1/2a open-label, multicenter, dose escalation and expansion study of mirdametinib in combination with BGB-3245 in adult participants with histologically confirmed, advanced (American Joint Committee on Cancer (AJCC) Stage III or IV) metastatic or unresectable solid cancer that is refractory to or has progressed during or after at least 1 line of appropriate prior systemic anti-cancer therapy including chemotherapy, immunotherapy, or appropriate targeted therapy, or for which there is no treatment available, or prior standard of care therapy was not tolerated.
The study will be conducted in two sequential parts: Part 1 dose escalation (Phase 1) and Part 2 dose expansion (Phase 2a).
Participants will receive mirdametinib and brimarafenib administered by mouth every day on a continuous schedule. Mirdametinib will be dosed twice a day (BID) and brimarafenib will be dosed once a day (QD). One treatment cycle will be 28 days.
Part 1 of the study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary evidence of anti-tumor efficacy. Part 1 will also identify the MTD and the RP2D for the combination of mirdametinib with brimarafenib.
Part 2 will confirm the safety, tolerability, efficacy, PK, and PDx for the combination of mirdametinib and brimarafenib. It will follow a parallel design and include one or more dose expansion cohorts, where each participant would be treated with the combination of mirdametinib and brimarafenib at the RP2D. It will begin after the RP2D for the combination of mirdametinib and brimarafenib is identified in Part 1. Part 2 may start either in parallel with, or after, the conduct and analysis of the PDx Expansion Cohort in Part 1.
Participants who experience a TEAE requiring treatment modification will be managed according to the applicable guidelines in the protocol.
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany is the lead sponsor of 14 studies on the registry; 6 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
First submitted before SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Part 2: oncogenic mutation or genomic aberration defined below:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with an oncogenic mutation or other genomic aberration of the MAPK pathway
Drug: Mirdametinib 2mg · Drug: BGB-3245 5mg
Participants with an oncogenic mutation or other genomic aberration of the MAPK pathway
Drug: Mirdametinib 2mg · Drug: BGB-3245 10mg
Participants with an oncogenic mutation or other genomic aberration of the MAPK pathway
Drug: Mirdametinib 2mg · Drug: BGB-3245 20mg
Participants with an oncogenic mutation or other genomic aberration of the MAPK pathway
Drug: Mirdametinib 3mg · Drug: BGB-3245 10mg
Participants with an oncogenic mutation or other genomic aberration of the MAPK pathway
Drug: Mirdametinib 4mg · Drug: BGB-3245 10mg
Mirdametinib 2mg administered orally
Also known as: PD-0325901
BGB-3245 5mg administered orally
Also known as: Brimarafenib
Mirdametinib 3mg administered orally
Also known as: PD-0325901
Mirdametinib 4mg administered orally
Also known as: PD-0325901
BGB-3245 10mg administered orally
Also known as: Brimarafenib
BGB-3245 20mg administered orally
Also known as: Brimarafenib
Incidence of Treatment Emergent Adverse Events
Safety and tolerability endpoint evaluation via incidence of treatment emergent Adverse Events (TEAEs). TEAE severities were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0. AEs were coded using MedDRA Version 27.1.
Time frame: All adverse events were collected from the time of signing ICF until 30 days after the last dose of study treatment (an average of 3.48 months and up to 16.76 months).
Maximum Tolerated Dose (Part 1 Only)
The maximum tolerated dose (MTD) for mirdametinib and BGB-3245 administered as a combination, if any, will be based on safety and tolerability during the first 28 days of treatment in Cycle 1.
Time frame: Up to 18 months
Recommended Phase 2 Dose [RP2D] (Part 1 Only)
The recommended phase 2 dose (RP2D) for mirdametinib and BGB-3245 administered as a combination will be determined based on safety, tolerability, PK, preliminary anti-tumor efficacy, and other available data.
Time frame: Up to 24 months
Objective Response Rate (Part 2 Only)
Preliminary anti-tumor efficacy for the RP2D of mirdametinib and BGB-3245 administered as a combination as assessed by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI). Objective Response Rate (ORR) defined as the proportion of participants with complete response (CR) + partial response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
Time frame: Up to 24 months
Objective Response Rate (Part 1 Only)
Preliminary anti-tumor efficacy of mirdametinib and BGB-3245 administered as a combination as assessed by CT or MRI. ORR defined as the proportion of participants with Complete Response (CR) + Partial Response (PR) using RECIST v1.1. Responses were as reported by the investigators.
Time frame: From participants' date of first dose of study treatment through end of treatment, an average of 3.5 months
Duration of Response Rate
Duration of response rate in participants treated with the combination of mirdametinib and BGB-3245, defined as the time from response (CR + PR using RECIST v1.1) to disease progression and/or death.
Time frame: Up to 36 months
Change in Plasma Concentrations of Mirdametinib and BGB-3245
To determine the PK of mirdametinib and BGB-3245 administered as a combination in the eligible participant population. Plasma concentrations of mirdametinib and BGB-3245 will be measured to evaluate systemic exposures (AUC, Cmax, Ctrough, and other PK parameters as data allow).
Time frame: Up to 24 months
Participants were enrolled in each Part 1 cohort following safety committee review. Study was terminated after Part 1 Cohort 5 was completed due to intolerance of the combination and no apparent early signs of efficacy. No participants were enrolled in Part 2 of the study.
| Milestone | Phase 1, Cohort 1 - Dose Escalation | Phase 1, Cohort 2 - Dose Escalation | Phase 1, Cohort 3 - Dose Escalation | Phase 1, Cohort 4 - Dose Escalation | Phase 1, Cohort 5 - Dose Escalation |
|---|---|---|---|---|---|
| Started | 3 | 7 | 6 | 4 | 3 |
| Completed | 3 | 3 | 1 | 3 | 1 |
| Not completed | 0 | 4 | 5 | 1 | 2 |
| Withdrew: Adverse event | 0 | 1 | 4 | 0 | 2 |
| Withdrew: Removal from study | 0 | 2 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 0 | 0 |
Safety and tolerability endpoint evaluation via incidence of treatment emergent Adverse Events (TEAEs). TEAE severities were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0. AEs were coded using MedDRA Version 27.1.
| Participants | Phase 1, Cohort 1 - Dose Escalation | Phase 1, Cohort 2 - Dose Escalation | Phase 1, Cohort 3 - Dose Escalation | Phase 1, Cohort 4 - Dose Escalation | Phase 1, Cohort 5 - Dose Escalation | Phase 1 Overall - Dose Escalation |
|---|---|---|---|---|---|---|
| With at least one TEAE | 3 | 7 | 6 | 4 | 3 | 23 |
| With at least one treatment-emergent SAE | 2 | 3 | 5 | 3 | 3 | 16 |
| With at least one study procedure related TEAE | 0 | 1 | 0 | 0 | 0 | 1 |
| With at least one TEAE leading to any treatment discontinuation | 0 | 2 | 4 | 2 | 3 | 11 |
| With at least one TEAE related to Mirdametinib | 2 | 6 | 5 | 4 | 3 | 20 |
| With at least one TEAE related to BGB-3245 | 3 | 6 | 5 | 4 | 3 | 21 |
| With at least one TEAE leading to Mirdametinib dose reduction | 1 | 2 | 1 | 1 | 0 | 5 |
| With at least one TEAE leading to BGB-3245 dose reduction | 0 | 2 | 1 | 1 | 0 | 4 |
| With at least one TEAE leading to Mirdametinib dose interruption | 2 | 2 | 5 | 2 | 2 | 13 |
| With at least one TEAE leading to BGB-3245 dose interruption | 2 | 3 | 5 | 2 | 2 | 14 |
| With a TEAE leading to discontinuation of Mirdametinib | 0 | 2 | 4 | 1 | 3 | 10 |
| With a TEAE leading to discontinuation of BGB-3245 | 0 | 1 | 4 | 2 | 3 | 10 |
| With at least one Mirdametinib treatment-emergent AE of special interest | 0 | 3 | 3 | 2 | 1 | 9 |
| With at least one BGB-3245 treatment-emergent AE of special interest | 0 | 3 | 4 | 2 | 1 | 10 |
The maximum tolerated dose (MTD) for mirdametinib and BGB-3245 administered as a combination, if any, will be based on safety and tolerability during the first 28 days of treatment in Cycle 1.
| mg | Phase 1 Overall - Dose Escalation |
|---|---|
| Maximum Tolerated Dose: BGB-3245 (QD) when given in combination with mirdametinib | 10 |
| Maximum Tolerated Dose: Mirdametinib (BID) when given in combination with BGB-3245 | 3 |
The recommended phase 2 dose (RP2D) for mirdametinib and BGB-3245 administered as a combination will be determined based on safety, tolerability, PK, preliminary anti-tumor efficacy, and other available data.
| Participants | Phase 1 Overall - Dose Escalation |
|---|---|
| Recommended Phase 2 Dose [RP2D] (Part 1 Only) | NA |
Preliminary anti-tumor efficacy for the RP2D of mirdametinib and BGB-3245 administered as a combination as assessed by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI). Objective Response Rate (ORR) defined as the proportion of participants with complete response (CR) + partial response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
No measurements were reported for this outcome.
Preliminary anti-tumor efficacy of mirdametinib and BGB-3245 administered as a combination as assessed by CT or MRI. ORR defined as the proportion of participants with Complete Response (CR) + Partial Response (PR) using RECIST v1.1. Responses were as reported by the investigators.
| Participants | Phase 1, Cohort 1 - Dose Escalation | Phase 1, Cohort 2 - Dose Escalation | Phase 1, Cohort 3 - Dose Escalation | Phase 1, Cohort 4 - Dose Escalation | Phase 1, Cohort 5 - Dose Escalation | Phase 1 Overall - Dose Escalation |
|---|---|---|---|---|---|---|
| Objective Response Rate (Part 1 Only) | 0 | 0 | 0 | 0 | 0 | 0 |
Duration of response rate in participants treated with the combination of mirdametinib and BGB-3245, defined as the time from response (CR + PR using RECIST v1.1) to disease progression and/or death.
No measurements were reported for this outcome.
To determine the PK of mirdametinib and BGB-3245 administered as a combination in the eligible participant population. Plasma concentrations of mirdametinib and BGB-3245 will be measured to evaluate systemic exposures (AUC, Cmax, Ctrough, and other PK parameters as data allow).
| ng/mL | Phase 1 Dose Escalation, Cohort 1 | Phase 1 Dose Escalation, Cohort 2 | Phase 1 Dose Escalation, Cohort 3 | Phase 1 Dose Escalation, Cohort 4 | Phase 1 Dose Escalation, Cohort 5 |
|---|---|---|---|---|---|
| BGB-3245 Cycle 1 Day 1 -Predose | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| BGB-3245 Cycle 1 Day 1-1 hr | 61.9 ± 38.64 | 76.9 ± 79.50 | 110.7 ± 70.99 | 139.9 ± 61.83 | 100.1 ± 15.49 |
| BGB-3245 Cycle 1 Day 1-2 hr | 74.9 ± 16.62 | 118.3 ± 79.66 | 321.2 ± 113.73 | 172.3 ± 42.62 | 186.0 ± 26.87 |
| BGB-3245 Cycle 1 Day 1-4 hr | 54.2 ± 7.98 | 100.8 ± 53.88 | 325.2 ± 96.65 | 166.0 ± 102.81 | 166.5 ± 14.85 |
| BGB-3245 Cycle 1 Day 22- Predose | 518.0 ± 293.09 | 404.7 ± 189.47 | 1675.0 ± 601.04 | 541.0 ± 322.44 | — |
| BGB-3245 Cycle 2 Day 1 - Predose | 361.7 ± 334.31 | 353.8 ± 160.65 | 1300.0 ± 84.85 | 486.3 ± 232.15 | — |
| BGB-3245 Cycle 2 Day 1 - 1 hr | 436.0 ± 370.99 | 498.2 ± 276.51 | 1350.0 ± 70.71 | 558.7 ± 307.00 | — |
| BGB-3245 Cycle 2 Day 1 - 2 hr | 377.3 ± 343.60 | 501.8 ± 374.16 | 1325.0 ± 162.63 | 606.3 ± 341.03 | — |
| BGB-3245 Cycle 2 Day 1 - 4 hr | 305.7 ± 195.88 | 365.8 ± 257.11 | 1225.0 ± 190.92 | 406.0 ± 163.72 | — |
| BGB-3245 Cycle 3 Day 1 -Predose | 596.3 ± 393.52 | 277.6 ± 271.99 | 1051.0 ± 281.43 | 9.1 | — |
| Mirdametinib Cycle 1 Day 1- Predose | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| Mirdametinib Cycle 1 Day 1- 1 hr | 82.9 ± 8.06 | 48.0 ± 24.75 | 59.9 ± 25.01 | 115.4 ± 44.31 | 163.5 ± 40.31 |
| Mirdametinib Cycle 1 Day 1- 2 hr | 39.2 ± 14.96 | 34.8 ± 14.73 | 36.6 ± 9.28 | 48.0 ± 12.34 | 64.6 ± 14.28 |
| Mirdametinib Cycle 1 Day 1- 4 hr | 18.2 ± 7.04 | 14.0 ± 4.32 | 13.6 ± 3.04 | 24.9 ± 5.59 | 23.6 ± 3.46 |
| Mirdametinib Cycle 1 Day 22- Predose | 35.4 ± 2.93 | 15.7 ± 7.18 | 13.0 ± 4.17 | 38.9 ± 11.88 | — |
| Mirdametinib Cycle 2 Day 1- Predose | 19.2 ± 16.86 | 10.9 ± 7.33 | 13.1 ± 2.40 | 28.9 ± 3.74 | — |
| Mirdametinib Cycle 2 Day 1- 1 hr | 90.1 ± 66.50 | 81.5 ± 72.15 | 48.0 ± 21.78 | 143.0 ± 14.42 | — |
| Mirdametinib Cycle 2 Day 1- 2 hr | 56.8 ± 18.86 | 46.9 ± 27.25 | 62.0 ± 41.51 | 100.4 ± 2.95 | — |
| Mirdametinib Cycle 2 Day 1- 4 hr | 36.2 ± 15.79 | 26.2 ± 11.38 | 24.1 ± 7.00 | 52.0 ± 8.64 | — |
| Mirdametinib Cycle 3 Day 1- Predose | 23.8 ± 13.60 | 10.3 ± 11.11 | 9.2 ± 4.06 | 0 ± 0.00 | — |
Collected over All SAEs and AEs were collected from the time of signing ICF until 30 days after the last dose of study treatment (an average of 3.48 months and up to 16.76 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1, Cohort 1 - Dose Escalation | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Phase 1, Cohort 2 - Dose Escalation | 1/7 (14.3%) | 3/7 (42.9%) | 7/7 (100%) |
| Phase 1, Cohort 3 - Dose Escalation | 0/6 (0%) | 5/6 (83.3%) | 5/6 (83.3%) |
| Phase 1, Cohort 4 - Dose Escalation | 1/4 (25%) | 3/4 (75%) | 4/4 (100%) |
| Phase 1, Cohort 5 - Dose Escalation | 1/3 (33.3%) | 3/3 (100%) | 3/3 (100%) |
| Phase 1 Overall | 3/23 (13%) | 16/23 (69.6%) | 22/23 (95.7%) |
| Event | Phase 1, Cohort 1 - Dose Escalation | Phase 1, Cohort 2 - Dose Escalation | Phase 1, Cohort 3 - Dose Escalation | Phase 1, Cohort 4 - Dose Escalation | Phase 1, Cohort 5 - Dose Escalation | Phase 1 Overall |
|---|---|---|---|---|---|---|
| SepsisInfections and infestations | 0/3 | 0/7 | 0/6 | 0/4 | 1/3 | 1/23 |
| PyrexiaGeneral disorders | 1/3 | 0/7 | 2/6 | 0/4 | 1/3 | 4/23 |
| Abdominal painGastrointestinal disorders | 0/3 | 1/7 | 0/6 | 0/4 | 1/3 | 2/23 |
| DehydrationMetabolism and nutrition disorders | 1/3 | 0/7 | 0/6 | 0/4 | 0/3 | 1/23 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/3 | 0/7 | 0/6 | 0/4 | 0/3 | 1/23 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 0/3 | 0/7 | 0/6 | 0/4 | 1/3 | 1/23 |
| Sinus tachycardiaCardiac disorders | 0/3 | 0/7 | 0/6 | 0/4 | 1/3 | 1/23 |
| MalnutritionMetabolism and nutrition disorders | 0/3 | 0/7 | 0/6 | 1/4 | 0/3 | 1/23 |
| Confusional statePsychiatric disorders | 0/3 | 0/7 | 0/6 | 1/4 | 0/3 | 1/23 |
| DeliriumPsychiatric disorders | 0/3 | 0/7 | 0/6 | 1/4 | 0/3 | 1/23 |
| Event | Phase 1, Cohort 1 - Dose Escalation | Phase 1, Cohort 2 - Dose Escalation | Phase 1, Cohort 3 - Dose Escalation | Phase 1, Cohort 4 - Dose Escalation | Phase 1, Cohort 5 - Dose Escalation | Phase 1 Overall |
|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/3 | 3/7 | 2/6 | 4/4 | 2/3 | 12/23 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 3/3 | 1/7 | 1/6 | 2/4 | 1/3 | 8/23 |
| NauseaGastrointestinal disorders | 1/3 | 3/7 | 2/6 | 3/4 | 2/3 | 11/23 |
| VomitingGastrointestinal disorders | 0/3 | 2/7 | 2/6 | 3/4 | 0/3 | 7/23 |
| FatigueGeneral disorders | 2/3 | 5/7 | 2/6 | 1/4 | 2/3 | 12/23 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 2/3 | 0/7 | 1/6 | 1/4 | 0/3 | 4/23 |
| Blood creatine phosphokinase increasedInvestigations | 2/3 | 3/7 | 4/6 | 1/4 | 1/3 | 11/23 |
| Aspartate aminotransferase increasedInvestigations | 2/3 | 0/7 | 1/6 | 2/4 | 1/3 | 6/23 |
| Blood creatinine increasedInvestigations | 2/3 | 1/7 | 0/6 | 0/4 | 0/3 | 3/23 |
| HeadacheNervous system disorders | 0/3 | 4/7 | 1/6 | 1/4 | 0/3 | 6/23 |
| Age, Continuous(years) | Phase 1, Cohort 1 - Dose Escalation | Phase 1, Cohort 2 - Dose Escalation | Phase 1, Cohort 3 - Dose Escalation | Phase 1, Cohort 4 - Dose Escalation | Phase 1, Cohort 5 - Dose Escalation | Total |
|---|---|---|---|---|---|---|
| Median | 72 (62.0 to 72.0) | 56 (49.0 to 64.0) | 54 (49.0 to 72.0) | 52 (50.5 to 54.5) | 41 (39.0 to 60.0) | 55 (49.0 to 64.0) |
| Sex: Female, Male(Participants) | Phase 1, Cohort 1 - Dose Escalation | Phase 1, Cohort 2 - Dose Escalation | Phase 1, Cohort 3 - Dose Escalation | Phase 1, Cohort 4 - Dose Escalation | Phase 1, Cohort 5 - Dose Escalation | Total |
|---|---|---|---|---|---|---|
| Female | 1 | 6 | 1 | 3 | 2 | 13 |
| Male | 2 | 1 | 5 | 1 | 1 | 10 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1, Cohort 1 - Dose Escalation | Phase 1, Cohort 2 - Dose Escalation | Phase 1, Cohort 3 - Dose Escalation | Phase 1, Cohort 4 - Dose Escalation | Phase 1, Cohort 5 - Dose Escalation | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 3 | 6 | 5 | 4 | 1 | 19 |
| Unknown or Not Reported | 0 | 1 | 1 | 0 | 2 | 4 |
| Race (NIH/OMB)(Participants) | Phase 1, Cohort 1 - Dose Escalation | Phase 1, Cohort 2 - Dose Escalation | Phase 1, Cohort 3 - Dose Escalation | Phase 1, Cohort 4 - Dose Escalation | Phase 1, Cohort 5 - Dose Escalation | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 1 | 0 | 0 | 3 |
| White | 3 | 5 | 2 | 3 | 1 | 14 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 2 | 1 | 2 | 5 |
| Region of Enrollment(participants) | Phase 1, Cohort 1 - Dose Escalation | Phase 1, Cohort 2 - Dose Escalation | Phase 1, Cohort 3 - Dose Escalation | Phase 1, Cohort 4 - Dose Escalation | Phase 1, Cohort 5 - Dose Escalation | Total |
|---|---|---|---|---|---|---|
| United States | 3 | 4 | 5 | 3 | 1 | 16 |
| Australia | 0 | 3 | 1 | 1 | 2 | 7 |
| Type of Cancer Diagnosis(Participants) | Phase 1, Cohort 1 - Dose Escalation | Phase 1, Cohort 2 - Dose Escalation | Phase 1, Cohort 3 - Dose Escalation | Phase 1, Cohort 4 - Dose Escalation | Phase 1, Cohort 5 - Dose Escalation | Total |
|---|---|---|---|---|---|---|
| Non-small Cell Lung Carcinoma | 0 | 1 | 0 | 0 | 0 | 1 |
| Colorectal Cancer | 0 | 0 | 2 | 1 | 1 | 4 |
| Ovarian Cancer | 0 | 1 | 0 | 0 | 1 | 2 |
| Melanoma | 2 | 3 | 2 | 1 | 1 | 9 |
| Pancreatic Cancer | 1 | 0 | 1 | 0 | 0 | 2 |
| Other | 0 | 2 | 1 | 2 | 0 | 5 |
| Time Since Initial Diagnosis(months) | Phase 1, Cohort 1 - Dose Escalation | Phase 1, Cohort 2 - Dose Escalation | Phase 1, Cohort 3 - Dose Escalation | Phase 1, Cohort 4 - Dose Escalation | Phase 1, Cohort 5 - Dose Escalation | Total |
|---|---|---|---|---|---|---|
| Median | 100.3 (29.2 to 187.9) | 63.1 (46.4 to 139.2) | 33.0 (26.6 to 103.2) | 14.9 (7.5 to 60.7) | 68.8 (68.8 to 68.8) | 60.2 (26.6 to 100.3) |
| Time Since First Metastatic Disease(months) | Phase 1, Cohort 1 - Dose Escalation | Phase 1, Cohort 2 - Dose Escalation | Phase 1, Cohort 3 - Dose Escalation | Phase 1, Cohort 4 - Dose Escalation | Phase 1, Cohort 5 - Dose Escalation | Total |
|---|---|---|---|---|---|---|
| Median | 68.3 (14.7 to 108.9) | 56.3 (24.6 to 60.2) | 36.1 (28.9 to 84.1) | 7.0 (6.4 to 52.8) | 79.3 (68.8 to 89.8) | 56.3 (24.6 to 68.8) |
7 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD supporting publicly available results will be evaluated for sharing.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code
Time frame: IPD from completed trials will be publicly available within 6 months after all of the following events: Approval of a product/new indication by major authorities (FDA, EMA, PMDA if requested) with no pending submissions Public results via primary manuscript or trial registry disclosure Legal authority to share data Privacy protections are in place If approval is not sought or development is globally discontinued, data will be publicly available within 18 months after global trial completion. Further information on how to request data can be found on our website bit.ly/IPD21
Access criteria: Qualified researchers may propose access to IPD from sponsored trials via https://vivli.org/members/ourmembers/.
Data sharing details ↗ · vivli.org
Ran from Feb 2023 to primary completion in Jan 2025, 23 months.
Results were first posted in May 2026, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Mirdametinib · Brimarafenib
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany →